- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03799692
Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer
Clinical Trial of Nanoparticle Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer
This is an open-label, single arm, two-stage Simon Design study for women with LuminalB/HER-2 Negative Breast Cancer treated with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin.
The primary objective of the trial is to evaluate of the efficacy and safety of Nanoparticle Albumin-Bound Paclitaxel Combined with Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer.
The primary endpoint of the study is to assess Pathological complete response rate(pCR)using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
The total number of patients to be included in this study is 78 patients.
The duration of the study, from first patient visit to last patient visit will be approximately 12 months.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200032
- Recruiting
- Department of Breast Surgery, Cancer Hospital, Fudan University
-
Contact:
- Zhimin Shao
- Phone Number: 88807 86(21)64175590
- Email: zhimingshao@yahoo.com
-
Principal Investigator:
- Zhimin Shao
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Zhi-Min Shao, MD.PhD.
- Phone Number: 13601637369
- Email: zhimingshao@yahoo.com
-
Principal Investigator:
- Zhi-Min Shao, MD.PhD.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1.Age: from 18 to 70 years old, female.
- 2.Has histologically or cytologically confirmed unilateral primary invasive breast cancer with a clinical stage of T2-4NanyM0.
- 3.Immunohistochemical detection of ER+, PR+, HER-2 negative (if HER2 expression is 2+ patients need to be confirmed by in situ hybridization to detect no HER-2 gene amplification) and Ki-67 expression >20% of patients;
- 4.At least one measurable objective lesion according to RECIST 1.1 criteria.
- 5.ECOG performance status of 0-1.
- 6.Bone marrow function: Neutrophils ≥ 1.5×109/L, platelets ≥ 100×109/L, and hemoglobin ≥ 90 g/L.
- 7.Liver and renal function: Serum creatinine ≤ 1.5 times the upper limit of normal. AST and ALT ≤ 2.5 times the upper limit of normal Total bilirubin ≤ 1.5 times the upper limit of normal, or ≤ 2.5 times the upper limit of normal in patients with Gilbert's syndrome.
- 8.Has good compliance with the planned treatment, understand the study process and sign written informed consent.
Exclusion Criteria:
- 1.Any prior cytotoxic chemotherapy, endocrine therapy, biological therapy, or radiation therapy.
- 2.Patients with grade II or higher heart disease scored by the New York Heart Association (NYHA).
- 3.Severe systemic infection, or with other serious diseases.
- 4.Patients with known hypersensitivity or intolerance to chemotherapeutic agents or their excipients.
- 5.Other malignancies have occurred in the past 5 years, except for cured cervical carcinoma in situ, non-melanoma skin carcinoma.
- 6.Pregnant or lactating, and who refuse to take appropriate contraception during the course of this trial.
- 7.Have participated in other study studies within 30 days prior to the first dose of study drug.
- 8.Patients who, in the opinion of the Investigator, are not suitable for participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Chemotherapy
Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, Carboplatin AUC=2, iv, d1, 8, 15, 4 cycles (21 days per cycle).
|
Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15. Drug: Carboplatin AUC=2 iv, d1, 8, 15. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary endpoint is pathological complete remission (pCR)
Time Frame: 3 months
|
Histopathological examination of breast and axillary lymph node specimens without invasive cancer cell remnants.
Complete pathological response is also considered to be achieved if only in situ cancer cell remnants are present in the surgical specimens.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: 3 months
|
The second endpoint ORR composed of tumor response classifications of complete response (CR) and partial response (PR), refers to the number of cases with complete and partial response after treatment as a percentage of the total number of evaluable cases.
|
3 months
|
Breast conserving surgery (BCS) rate
Time Frame: 3 months
|
Percentage of patients undergoing breast-conserving surgery after neoadjuvant therapy as a whole evaluable.
|
3 months
|
Adverse events (AE)
Time Frame: 3 months
|
Adverse events (AE) were monitored on an ongoing basis and classified according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.
Patients were assessed for toxicities before each administration, and toxicity was graded accordingly.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zhimin Shao, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1808189-8
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER-2 Negative Breast Cancer
-
Henan Cancer HospitalQilu Pharmaceutical Co., Ltd.; Beijing Biostar Pharmaceuticals Co., Ltd.Not yet recruitingHER-2 Negative Breast Cancer
-
Nanjing Chia-tai Tianqing PharmaceuticalRecruitingHR Positive/HER-2 Negative Breast CancerChina
-
Ying LinRecruitingHer-2 Negative Breast Cancer | HRR Gene MutationChina
-
Fudan UniversityRecruitingHormone Receptor Positive HER-2 Negative Breast CancerChina
-
University Hospital TuebingenUniversity Hospital Freiburg; University Hospital UlmRecruitingHormone Receptor Positive HER-2 Negative Breast CancerGermany
-
Georgetown UniversityUniversity of Chicago; Thomas Jefferson UniversityCompletedHormone Receptor Positive HER-2 Negative Breast CancerUnited States
-
Osaka Medical CollegeTerminatedBreast Cancer | HER-2 Positive Breast Cancer | Estrogen Receptor Negative NeoplasmJapan
-
Synta Pharmaceuticals Corp.CompletedBreast Cancer | Triple Negative Breast Cancer | HER-2 Positive Breast Cancer | ER/Progressive Response (PR) + Refractory to Prior Hormonal TreatmentSpain, United States, Argentina, Belgium, Brazil, Korea, Republic of, Peru, United Kingdom
-
Adrienne G. WaksEli Lilly and Company; Verastem, Inc.RecruitingBreast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast CancerUnited States
-
iOMEDICO AGNovartis PharmaceuticalsCompletedBreast Cancer | Hormone Receptor Positive Tumor | HER 2 Negative Breast CancerGermany
Clinical Trials on Chemotherapy
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia | Adult Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingColorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Colorectal Carcinoma Metastatic in the LungUnited States, Canada
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
International Atomic Energy AgencyCompletedNon Small Cell Lung CancerChile, China, Croatia, Egypt, India, Malaysia, Malta, Morocco, Pakistan, Panama, Peru, South Africa, Tunisia
-
Ping LiangNot yet recruitingChemotherapy | Liver Metastases | Colorectal Carcinoma
-
Second Affiliated Hospital, School of Medicine,...UnknownUnresectable Gastric Cancer | Successful Conversion Rate of OperationChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Yantai Yuhuangding HospitalRecruiting
-
Shenzhen SiBiono GeneTech Co.,LtdUnknown
-
Ruijin HospitalNot yet recruitingGastric Cancer | Neoadjuvant ChemotherapyChina